Specific hepatic delivery of procollagen 1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis

被引:101
作者
Calvente, Carolina Jimenez [1 ,2 ]
Sehgal, Alfica [3 ]
Popov, Yury [4 ]
Kim, Yong Ook [1 ,2 ]
Zevallos, Victor [1 ,2 ]
Sahin, Ugur [2 ,5 ]
Diken, Mustafa [2 ,5 ]
Schuppan, Detlef [1 ,2 ,4 ]
机构
[1] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Translat Immunol, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Med Ctr, Res Ctr Immunotherapy, D-55131 Mainz, Germany
[3] Alnylam Pharmaceut, Cambridge, MA USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
[5] Ctr Translat Oncol, Mainz, Germany
基金
美国国家卫生研究院;
关键词
IN-VIVO; CHAPERONE; CELLS; SIRNA; PHAGOCYTOSIS; LIPOSOMES; CIRRHOSIS; TARGET; MATRIX; SIZE;
D O I
10.1002/hep.27936
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Fibrosis accompanies the wound-healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I. Fibrosis often progresses to cirrhosis. Here we present in vivo evidence of an up to 90% suppression of procollagen 1(I) expression, a reduction of septa formation, and a 40%-60% decrease of collagen deposition in mice with progressive and advanced liver fibrosis that received cationic lipid nanoparticles loaded with small interfering RNA to the procollagen 1(I) gene. After intravenous injection, up to 90% of lipid nanoparticles loaded with small interfering RNA to the procollagen 1(I) gene were retained in the liver of fibrotic mice and accumulated in nonparenchymal more than parenchymal cells for prolonged periods, significantly ameliorating progression and accelerating regression of fibrosis. Conclusion: Our lipid nanoparticles loaded with small interfering RNA to the procollagen 1(I) gene specifically reduce total hepatic collagen content without detectable side effects, potentially qualifying as a therapy for fibrotic liver diseases. (Hepatology 2015;62:1285-1297)
引用
收藏
页码:1285 / 1297
页数:13
相关论文
共 30 条
[1]   Nonviral delivery of synthetic siRNAs in vivo [J].
Akhtar, Saghir ;
Benter, Ibrahim F. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3623-3632
[2]  
Akinc A, 2014, GENE CELL THERAPY TH, P493
[3]   Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver [J].
Akinc, Akin ;
Goldberg, Michael ;
Qin, June ;
Dorkin, J. Robert ;
Gamba-Vitalo, Christina ;
Maier, Martin ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Roehl, Ingo ;
Leshchiner, Elizaveta S. ;
Langer, Robert ;
Anderson, Daniel G. .
MOLECULAR THERAPY, 2009, 17 (05) :872-879
[4]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[5]   VITAMIN-A METABOLISM - NEW PERSPECTIVES ON ABSORPTION, TRANSPORT, AND STORAGE [J].
BLOMHOFF, R ;
GREEN, MH ;
GREEN, JB ;
BERG, T ;
NORUM, KR .
PHYSIOLOGICAL REVIEWS, 1991, 71 (04) :951-990
[6]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[7]  
Danladi J, 2014, IOSR J DENT MED SCI, V13, P53
[8]   Mechanisms of hepatic fibrogenesis [J].
Friedman, Scott L. .
GASTROENTEROLOGY, 2008, 134 (06) :1655-1669
[9]  
Friedman SL, 2013, J HEPATOL, V58, P1, DOI 10.1016/j.jhep.2012.10.014
[10]   Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover [J].
Gineyts, E ;
Cloos, PAC ;
Borel, O ;
Grimaud, L ;
Delmas, PD ;
Garnero, P .
BIOCHEMICAL JOURNAL, 2000, 345 :481-485